Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Dosage Forms × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Genitourinary 1

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

Dexamethasone 138 Lenalidomide 75 Cyclophosphamide 72 Bortezomib 72 Calcium Dobesilate 57 fludarabine 49 pomalidomide 43 daratumumab 39 fludarabine phosphate 33 carfilzomib 33 Melphalan 29 dexamethasone acetate 24 dexamethasone 21-phosphate 24 auricularum 22 Filgrastim 18 Whole-Body Irradiation 15 Biopsy 14 ixazomib 13 isatuximab 13 Magnetic Resonance Spectroscopy 13 Granulocyte Colony-Stimulating Factor 13 Vorinostat 12 Tacrolimus 12 Specimen Handling 12 Peripheral Blood Stem Cell Transplantation 12 venetoclax 11 Sirolimus 11 Rituximab 11 belantamab mafodotin 10 Panobinostat 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡